HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of a Response
Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination
with Peginterferon (either alpha 2b or alpha 2a) and Ribavirin in HIV/HCV genotype 1 infected
patients that failed to previous HCV therapy.